peptide-solutions

GLP2-TRZ

Dual GLP-1/GIP receptor agonist for metabolic research

Research Compound

Manufactured under strict quality control protocols with full analytical testing. Certificate of Analysis (COA) available upon request.

Purity: >98%Form: LyophilizedStorage: -20°CGrade: Research

Top Seller

Tirzepatide is a dual GIP/GLP-1 receptor agonist approved for type 2 diabetes and obesity treatment. Research explores its exceptional efficacy in weight reduction and metabolic improvement.

Compound Specifications

Purity Level>98%

Physical FormLyophilized powder (10mg/vial)

1. Choose dose

Select the amount contained in each vial.

2. Choose quantity option

Choose one vial, or choose a kit with 10 units priced as 8.

$109USD

Amount per vial: 10mg

3. Cart quantity:

Research-Grade

COA Available

Tracked Shipping

Third-Party Tested

Scientific Documentation

Research Reference

Detailed research information, pharmacological profile, and handling specifications

Mechanism of Action

A single molecule activating both GIP receptor (GIPR) and GLP-1 receptor (GLP-1R). The dual mechanism produces greater insulin secretion, appetite suppression, and fat cell remodeling than GLP-1 agonism alone.

Verified Buyer Reviews

What researchers say

Loading reviews...

Research Use Only Disclaimer

This product is intended strictly for laboratory and research purposes only. Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease. By purchasing, you confirm that you are an authorized researcher or institution and that this product will be used solely for legitimate research purposes in compliance with all applicable laws and regulations.